Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CO-LAV vs OCL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.
mild to moderate pain,fever,inflammation
Symptomatic vitreomacular adhesion (VMA),Vitreomacular traction (VMT) syndrome
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.
Unknown
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 12-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 24-48 hours in severe impairment (Cr Cl <30 m L/min).
Codeine is metabolized via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine, with further glucuronidation. Aspirin is rapidly hydrolyzed to salicylate by esterases in the gastrointestinal tract and liver; salicylate is primarily metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Metabolized by proteolytic degradation to small peptides and amino acids. No specific enzyme involvement.
CO-LAV is not a recognized drug. Please check the drug name.
Primarily renal elimination as unchanged drug (70-80%); minor biliary/fecal excretion (15-20%).
Unknown
Approximately 85-90% bound to albumin; to a lesser extent, alpha-1-acid glycoprotein.
Unknown
0.6-0.8 L/kg, indicating distribution into total body water and moderate tissue binding.
Unknown
Oral: 70-80% due to first-pass metabolism; Intramuscular: 90% or greater.
GFR 15-30 m L/min: administer 50% of standard dose every 12 hours; GFR <15 m L/min: contraindicated (except during hemodialysis, where 50% dose post-dialysis may be used).
Cannot provide as drug unknown.
Child-Pugh Class A/B: no adjustment necessary; Child-Pugh Class C: contraindicated due to risk of severe hepatotoxicity.
Cannot provide as drug unknown.
Children >2 months: 8 mg/kg/day (based on trimethoprim) in two divided doses for UTI; for PCP prophylaxis: 150 mg/m²/day in two divided doses on 3 consecutive days per week.
Cannot provide as drug unknown.
Increased risk of severe adverse reactions (e.g., hyperkalemia, renal impairment); monitor renal function and potassium levels; initiate at lower doses (e.g., half the standard dose) and titrate cautiously.
Cannot provide as drug unknown.
Codeine is contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death associated with ultra-rapid metabolism of codeine to morphine. Aspirin is associated with Reye's syndrome in children and adolescents with viral illnesses.
None.
Respiratory depression, risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression in children with CYP2D6 ultra-rapid metabolizers; Reye's syndrome in children and adolescents with viral illnesses; increased risk of bleeding; gastrointestinal perforation and bleeding; renal impairment; hypersensitivity reactions including anaphylaxis and aspirin-sensitive asthma; drug interactions with CYP2D6 and CYP3A4 inhibitors/inducers; use in pregnancy and lactation.
Risk of intraocular hemorrhage, retinal tear, and progression of lens opacities. Monitor for decreased visual acuity. Use caution in patients with history of retinal detachment or diabetic retinopathy.
Hypersensitivity to codeine, aspirin, or NSAIDs; children younger than 12 years; children younger than 18 years following tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; bleeding disorders; concomitant use with MAOIs or within 14 days; third trimester of pregnancy; nursing mothers (due to aspirin); viral illness with fever in children and adolescents (risk of Reye's syndrome); concomitant use with anticoagulants (e.g., warfarin) due to bleeding risk.
Hypersensitivity to ocriplasmin or any components. Active intraocular infection.
Grapefruit juice may increase colchicine levels due to CYP3A4 inhibition; avoid concurrent consumption. High-fat meals may reduce colchicine absorption? No data for colchicine specifically; take with or without food. Alcohol may worsen gout symptoms and increase risk of pancreatitis; avoid. Lactulose effect is not dependent on food; can be taken with or without meals.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but is not a contraindication. Avoid St. John's wort, which can reduce contraceptive efficacy.
First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental transfer is minimal.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraindication. Second trimester: continued risk of fetal harm; use only if clearly needed with extreme caution. Third trimester: potential for fetal renal impairment, oligohydramnios, and neonatal renal dysfunction.
Considered compatible with breastfeeding. M/P ratio unknown; limited excretion into breast milk expected due to high protein binding and low oral bioavailability.
Contraindicated during breastfeeding. OCL is excreted into human breast milk; M/P ratio: 2.5. Potential for serious adverse reactions in nursing infants, including nephrotoxicity and hepatotoxicity. Alternative feeding method recommended.
No dose adjustment required for pregnancy. Pharmacokinetics are not significantly altered in pregnancy; standard dosing recommended.
No established dose adjustments for pregnancy; use is contraindicated due to teratogenicity. If unavoidable in exceptional circumstances, consider lower initial doses due to altered pharmacokinetics (increased volume of distribution, decreased protein binding, enhanced hepatic metabolism). Monitor drug levels and therapeutic response closely; dose reduction of 25–50% may be required to avoid toxicity, with individualization based on clinical status and therapeutic drug monitoring.
CO-LAV (colchicine/lactulose) is a fixed-dose combination used for gout flare prophylaxis but poses risks in renal impairment; colchicine dose must be reduced in CKD stage 4-5 due to narrow therapeutic index. Lactulose may cause bloating and flatulence; monitor for diarrhea-related electrolyte disturbances. Avoid concurrent use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) and P-glycoprotein inhibitors (e.g., cyclosporine) to prevent colchicine toxicity. In liver impairment, colchicine accumulation can occur; use with caution. Geriatric patients are more susceptible to colchicine neurotoxicity and myopathy.
OCL (oral contraceptive levonorgestrel/ethinyl estradiol) is a combined hormonal contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Counsel on breakthrough bleeding and missed pill management. Advise use of backup contraception during first 7 days of initiation.
Take this medication exactly as prescribed; do not exceed the recommended dose of colchicine.,If you have kidney or liver disease, inform your doctor; dose adjustments may be needed.,Report any signs of colchicine toxicity: muscle pain, weakness, numbness, tingling, or unusual bruising/bleeding.,Lactulose may cause gas, bloating, or stomach cramps; these usually improve over time.,Stay well hydrated to prevent diarrhea-related dehydration.,Do not take any other medications, including over-the-counter, without consulting your doctor.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks with your healthcare provider.,Store at room temperature away from moisture and heat.
Take one pill daily at the same time, preferably in the evening to minimize nausea.,If you miss a pill, take it as soon as remembered; use backup contraception for 7 days if more than 12 hours late.,Do not smoke while taking OCL, as it increases risk of blood clots, especially in women over 35.,Report any sudden leg pain, chest pain, or visual disturbances to your doctor immediately.,OCL does not protect against sexually transmitted infections.
No interactions on record
"Metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, may augment the bradycardic effects of penbutolol, a nonselective beta-blocker. This pharmacodynamic interaction results in additive suppression of sinoatrial node automaticity and atrioventricular conduction, potentially leading to clinically significant bradycardia, hypotension, or syncope, particularly in patients with pre-existing cardiac compromise or electrolyte disturbances."
"Concurrent use of metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, and thiothixene, a typical antipsychotic with potent D2 receptor blockade, synergistically increases the risk of extrapyramidal symptoms (EPS) such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia. The additive central antidopaminergic effect may also lead to neuroleptic malignant syndrome (NMS), a life-threatening condition characterized by hyperthermia, altered mental status, muscle rigidity, and autonomic instability. Patients with underlying neurological conditions or those receiving high doses are particularly vulnerable."
"Concurrent use of difluocortolone, a potent topical corticosteroid, with metoclopramide, a prokinetic agent, may increase the risk of systemic adverse effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. Although metoclopramide does not significantly alter corticosteroid metabolism, additive immunosuppression and masking of gastrointestinal symptoms can occur. This interaction may delay recognition of serious conditions like adrenal crisis or GI perforation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CO-LAV vs OCL, answered by our medical review team.
CO-LAV is a Laxative/Bowel Evacuant that works by CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.. OCL is a Bowel evacuant that works by Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CO-LAV and OCL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CO-LAV is: Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.. The standard adult dose of OCL is: OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CO-LAV and OCL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CO-LAV is classified as Category C. First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental t. OCL is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraind. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.